Verseon Corporation Result of Special Meeting & Board Appointment (1396U)

TIDMVSN

RNS Number : 1396U

Verseon Corporation

20 October 2017

 
 Press release   October 20, 2017 
 

Verseon Corporation

("Verseon" or the "Company")

Results of Special Shareholder Meeting and Appointment of Dr. Robert W. Karr to the Board of Directors

FREMONT, Calif.-Verseon Corporation (AIM:VSN), a technology-based pharmaceutical company, is pleased to announce that Dr. Robert W. Karr was elected as a Non-Executive Class II Director ("Director") of the Company, effective immediately, at the Company's Special Shareholder Meeting ("Special Meeting") held on October 19, 2017 at 14:00 PDT.

As detailed in the announcement of the Special Meeting made on September 25, 2017, Dr. Karr has previously served in a range of senior management roles in the pharmaceutical and biotech industry, including Senior Vice President of R&D Strategy at Pfizer and Chief Scientific Officer at Tioma Therapeutics. He brings to Verseon broad expertise spanning drug discovery and development, clinical trials, as well as investor relations and partnering efforts.

Commenting on Dr. Karr's appointment, Adityo Prakash, Chief Executive Officer said: "We are delighted to welcome Dr. Karr to Verseon's Board of Directors. For many years he has helped shape Verseon's drug programs as a member of our Scientific Advisory Board, and we are excited that he has now agreed to serve as a Non-Executive Director. Verseon is entering a significant period as we prepare to advance some of our drug programs into clinical trials. With his wealth of experience and unique understanding of the global pharmaceutical industry, Dr. Karr will provide valuable leadership and strategic insight."

"I am excited to join Verseon's Board of Directors," said Dr. Karr. "I have supported the Company since its early years because I recognized the potential impact of Verseon's disruptive platform on drug discovery. The recent results across the Company's pipeline, and in particular the progress toward clinical trials, show that Verseon is realizing this potential. I look forward to working with Verseon's interdisciplinary team."

Other Information

In relation to the appointment of Dr. Karr, the Company confirms that there is no further information to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules for Companies save as disclosed below:

 
 Full Name:                     Robert William Karr 
-----------------------------  -------------------------- 
 Age:                           69 
-----------------------------  -------------------------- 
 Current Directorships          Tansna Therapeutics, Inc. 
  / Partnership: 
-----------------------------  -------------------------- 
 Previous Directorships         Idera Pharmaceuticals, 
  / Partnership in the past      Inc. 
  5 years:                       Vasculox, Inc. 
                                 Antegrin Therapeutics 
                                 LLC 
                                 Mencuro Therapeutics, 
                                 Inc. 
                                 Medros, Inc. 
-----------------------------  -------------------------- 
 Shareholding in the Company    185,264 shares 
-----------------------------  -------------------------- 
 

- Ends -

For further information, please contact

 
 Verseon Corporation                www.verseon.com 
                                       +1 (510) 225 
 Tina Schlafly                                 9000 
 
 Cenkos Securities (NOMAD and 
  Joint Broker) 
                                         +44 (0) 20 
 Neil McDonald / Beth McKiernan           7397 8900 
 
 Cantor Fitzgerald Europe (Joint 
  Broker) 
 Marc Milmo / Phil Davies /              +44 (0) 20 
  Callum Butterfield                      7894 7000 
 
 Mirabaud Securities LLP (Joint 
  Broker) 
                                         +44 (0) 20 
 Peter Krens                              7321 2508 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd 
  (PR Advisers) 
 Henry Harrison-Topham / Jamie    +44 (0) 20 
  Hooper                           7466 5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 
 Simon Vane Percy             821 890 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLFFVLIVLALID

(END) Dow Jones Newswires

October 20, 2017 02:00 ET (06:00 GMT)